When does the panel meet?
The Business Expert Panel met once in May 2008, and plans to meet in November 2008. Its predecessor, the Industry Expert Panel, met three times in 2006.
What is the panel's mission?
The mission of the panel is to:
- Provide perspectives on the fast-changing environment for the conduct and organization of business R&D and business-user data needs.
- Identify emerging issues and trends that are important to maintaining the accuracy and relevance of the Business Research and Development Survey (BRDIS).
- Develop recommendations on priorities and strategies for ongoing activities and new directions to maintain the relevance and utility of the statistics produced from the Business R&D and Innovation Survey.
- Develop recommendations on ways to introduce the new survey to the business community to make companies aware of the importance of the survey data and to generate support for the survey.
Who are the 2008 panel members?
Biographical sketches of the 18 members of the 2008 Business Expert Panel Members are given below.
Mark Bernstein has led Palo Alto Research Center Incorporated (PARC), one of the world's premier centers of innovation, since 2001. He was named President and Center Director at this time to lead PARC in its transition from the Xerox research division to an independent research company. Under Mr. Bernstein's leadership, PARC has broadened its research and commercial focus while retaining close strategic ties with Xerox.
Since Mr. Bernstein assumed his role, PARC has entered into strategic research engagements with multiple government agencies and industry partners. PARC's commercial relationships include industry leaders in consumer electronics, biomedical sciences, enterprise computing, and renewable energy. Current non-confidential clients include top PC manufacturer and IT service provider Fujitsu Ltd., and one of the world's leading commercial printing companies, Dai Nippon Printing Co.
Motivated by his passion for moving products out of the research lab and into commercial applications, Mr. Bernstein has re-defined PARC's business strategy, streamlined organizational structure, and expanded customer relationships. He oversees nearly 200 of the world's leading experts in fields as diverse as materials science, distributed computing, human factors, mathematics, linguistics, and sociology.
Mr. Bernstein worked closely with PARC's previous leadership as Manager of Research Strategy under John Seely Brown (1992–1999), and as Associate Center Director under Michael Paige (2000). Mr. Bernstein came to PARC in 1979 with a broad background in the semiconductor industry. He joined the former General Sciences Laboratory as a researcher and later participated in the laboratory's joint venture Spectra Diode Laboratories (which later merged with JDS Uniphase).
Mr. Bernstein received his B.S. in Mechanical Engineering from the University of Colorado and an M.B.A. from the College of Notre Dame.
Mark Bregman is the Executive Vice President and Chief Technology Officer of Symantec. He is responsible for the Symantec Research Labs, emerging technologies, architecture and standards, and developing the technology strategy for the company. He also guides Symantec's investments in advanced research and is responsible for the development centers in India and China. In addition, Dr. Bregman leads the field technical enablement team, which works closely with the technical sales team to ensure they are prepared to assist customers in managing the impact of changing and emerging technical requirements.
Dr. Bregman joined Symantec through the company's merger with VERITAS Software. At VERITAS, he served as chief technology officer and was responsible for cross-product integration, advanced product development, merger and acquisition strategy, and the company's engineering development centers in Pune, India and Beijing, China. He also served as VERITAS' executive vice president in charge of product operations. Prior to joining VERITAS in 2002, Dr. Bregman was CEO of Airmedia, a wireless Internet firm. Previously he spent 16 years at IBM where he led the RS/6000 and Pervasive Computing divisions and held senior management positions in IBM Research and IBM Japan. He was also technical assistant to IBM CEO Lou Gerstner.
Dr. Bregman holds a Bachelor's in Physics from Harvard College and a Master's and Doctorate in Physics from Columbia University. He is a member of the Visiting Committee to the Harvard University Libraries, a member of the American Physical Society, and a senior member of IEEE. He also serves on the Board of Directors of ShoreTel.
George Dies is Director of Strategic Planning and Research Operations for Hewlett-Packard (HP) Laboratories. He is responsible for formulation and implementation of the Labs' research strategy, as well as supervision of the Labs' support services.
Mr. Dies joined HP in 2000 as part of Strategy and Corporate Development, where he supported the Personal Systems Group, Global Operations, and HP Labs in their M&A and alliance activities. He came to HP from Palo Alto Products International (now part of Flextronics), a designer and contract manufacturer for clients like Dell, HP, Palm, and Gateway. Prior to that, Mr. Dies worked for seven years each in a variety of finance and administrative roles at Spectra-Physics, Inc., a world leader in lasers and analytical equipment, and Raychem Corporation, a leading materials science company. Before starting his business career, Mr. Dies spent seven years in the U.S. Foreign Service, working in Washington DC, Benin, and Turkey in a variety of roles.
Mr. Dies has an undergraduate degree in Economics and French from Princeton University and an M.B.A. from Stanford University's Graduate School of Business. He is fluent in French, German, and Dutch.
Miles P. Drake
Miles Drake is Senior Vice President, Research and Development, and Chief Technology Officer of Weyerhaeuser. He oversees a research department devoted to growing the core businesses, supporting Weyerhaeuser's customers and creating new technical-based options for growth for the corporation.
Prior to joining Weyerhaeuser in 2006, Dr. Drake was with Air Products and Chemicals, Inc. (APCI), where he served as vice president, research and development, and chief technology officer since 2001. Dr. Drake joined APCI in 1986 as a European technology manager based in London and held numerous other leadership positions. In 2004–2005 he served as chairman of the Industrial Research Institute, an organization of 200 global companies focused on enhancing the effectiveness of technological innovation.
Dr. Drake holds a Ph.D. from Bristol University School of Surface Chemistry and a B.A. in Natural Science from Cambridge University, UK. He has served as a board member of the Board of Chemical Science & Technology of The National Academies.
Ronald Dressler is the Senior Manager of the Global R&D Planning Department of The Hershey Company, a leading snack food company located in Hershey, Pennsylvania. His group is responsible for strategic technology planning, open innovation, and project administration. He joined Hershey in 1983 after 9 years with Ralston Purina where he established technology planning for the Protein Technologies Division. Prior to his position at Ralston, Mr. Dressler was a chemist for Anheuser-Busch Inc.
Mr. Dressler received his Bachelor's degree in Chemistry from Benedictine College and his M.B.A. from St. Louis University. He has authored several papers in the areas of rapid product development and the measurement of R&D productivity. He is a member of the Institute of Food Technologists, the Society of Competitive Information Professionals, and the World Future Society. He is past chair of the Board of Editors for Research-Technology Management, the journal of the Industrial Research Institute (IRI), and is currently a member of IRI's Board of Directors.
Mary L. Good
Mary Good is the Donaghey University Professor at the University of Arkansas at Little Rock, and serves as Dean for the College of Engineering and Information Technology. She is managing member for the Fund for Arkansas' Future, LLC (an investment fund for start-up and early stage companies), past President of the AAAS, past President of the ACS, and an elected member of the National Academy of Engineering. She presently serves on the Boards of Acxiom, Inc., St. Vincent Health System, and Delta Bank and Trust.
Previously Dr. Good served a four-year term as the Under Secretary for Technology for the Technology Administration in the Department of Commerce, a presidentially appointed, Senate confirmed, position. In addition, she chaired the National Science and Technology Council's Committee on Technological Innovation (NSTC/CTI), and served on the NSTC Committee on National Security. Previously she served as the Senior Vice President for Technology for Allied Signal and as the Boyd Professor of Chemistry and Materials Science at Louisiana State University.
Dr. Good was appointed to the National Science Board by President Carter in 1980 and by President Reagan in 1986. She was the chair of that board from 1988–1991, when she received an appointment by President Bush to be a member of the President's Council of Advisors on Science and Technology. She has received many awards, including the National Science Foundation's Distinguished Public Service Award, the American Institute of Chemists' Gold Medal, the Priestly Medal from the American Chemical Society, and the Vannevar Bush Award from the National Science Board, among others.
Dr. Good received a Bachelor's in Chemistry from the University of Central Arkansas and an M.S. and Ph.D. in Inorganic Chemistry from the University of Arkansas at Fayetteville.
Paul M. Horn
Paul Horn was named New York University (NYU) Distinguished Scientist in Residence and NYU Stern Executive in Residence in September of 2007. Prior to his NYU position he was Senior Vice President of the IBM Corporation and Executive Director of Research. In this job he directed IBM's worldwide Research program with 3200 technical employees in eight sites in five countries, and helped guide IBM's overall technical strategy.
In his 28 years with IBM, Dr. Horn was a champion for translating technology based research into marketplace opportunities. Trained as a solid state physicist, he has held key management positions in science, semiconductors, and storage, successfully applying these disciplines to solving real world technology problems. Dr. Horn's top priority as head of IBM's Research Division was to stimulate innovation and innovative business models and quickly bring those innovations into the marketplace to sustain and grow IBM's businesses, and to create the new businesses of IBM's future.
Prior to joining IBM in 1979, Dr. Horn was a professor of Physics in the James Franck Institute and the Physics Department and at the University of Chicago. He graduated from Clarkson College of Technology and received his Doctorate in Physics from the University of Rochester in 1973. He is a Fellow of the American Physical Society and was an Alfred P. Sloan Research Fellow from 1974–1978. He is a member of the National Academy of Engineering, a former Associate Editor of Physical Review Letters, and has published over 85 scientific and technical papers.
Dr. Horn has received numerous awards including the 1988 Bertram Eugene Warren award from the American Crystallographic Association, the 2000 Distinguished Leadership award from the New York Hall of Science, the 2002 Hutchison Medal from the University of Rochester, and the 2002 Pake Prize from the American Physical Society. In 2003 Dr. Horn was named as one of the top computing business leaders in the U.S. by Scientific American magazine. He is also a member of numerous professional committees including three in Washington: the GAO (General Accountability Office) board of advisors, the Gallaudet University Advisory Board, and the board of trustees of the Committee for Economic Development. He is also on the board of trustees for Clarkson University and New York Polytechnic and on the UC Berkeley Industrial Advisory Board. He is a trustee of the New York Hall of Science.
Edward M. Hummel
Edward Hummel is Director of Business Development for Bell Laboratories, the research division of Alcatel-Lucent. In this role Dr. Hummel has been involved in setting up numerous research programs with government agencies in the United States and throughout the world. He also manages collaborative research and development programs with industrial and academic partners. Previously Dr. Hummel performed research in distributed multi-processing networks, simulation and modeling of physical processes, and high energy interactions of hadronic particles.
Dr. Hummel received his Ph.D. in Particle Physics from New York University and his M.B.A. from the Wharton School, University of Pennsylvania. He has served on the board of directors of the Chemical, Biological, and Radiological Technology Alliance and currently is on the board of the Industrial Research Institute.
Ray O. Johnson
Ray Johnson is the Senior Vice President and Chief Technology Officer of the Lockheed Martin Corporation. Dr. Johnson guides the Company's technology vision and provides corporate leadership in the strategic areas of Technology and Engineering, which include more than 65,000 people working on more than 4,000 programs. Dr. Johnson also leads the Corporation's Advanced Concepts Organization and the Center for Innovation, a world-class laboratory for collaborative experimentation and analysis involving Lockheed Martin, its customers, and industry partners.
Before joining Lockheed Martin, Dr. Johnson was the Chief Operating Officer for Modern Technology Solutions, Inc. (MTSI), of Alexandria, Virginia. Prior to that, he held a variety of increasingly responsible executive positions with Science Applications International Corporation (SAIC), including Senior Vice President and General Manager of the Advanced Concepts Business Unit. In addition to executive leadership and management positions, Dr. Johnson has experience in strategic planning, program development, program management, and venture capital funding. He currently serves as a member of the Sandia Corporation, the SPIE, and Project Lead the Way Boards of Directors. Dr. Johnson is a member of the Board of Visitors for the Clark School of Engineering at the University of Maryland. He previously served on the boards of two biotechnology companies.
Dr. Johnson was a member of the Air Force Scientific Advisory Board from 2001 to 2005, where he chaired the 2003 Summer Study titled, Unmanned Aerial Vehicles in Perspective: Effects, Capabilities, and Technologies, and co-chaired the 2002 Summer Study titled, Predictive Battlespace Awareness. He participated in several additional Summer Studies and Science and Technology Reviews. His Air Force career included assignments in laser physics and systems design and analysis, electro-optic systems research and development, survivability, and command and control. He is a member of the Institute of Electrical and Electronics Engineers (IEEE), the International Society for Optical Engineering (SPIE), Eta Kappa Nu, Tau Beta Pi, and Phi Kappa Phi.
Dr. Johnson holds a B.S. degree in Electrical Engineering from Oklahoma State University and M.S. and Ph.D. degrees in Electrical Engineering from the Air Force Institute of Technology.
Darren McKnight is Vice President for Technologies and Innovation for Agilex Technologies, Inc., based in Chantilly, Virginia. His primary responsibilities revolve around the development and implementation of advanced technologies to leverage information possessed by organizations to empower better decision-making. He is focused on space systems/environment analysis, information architectures, innovation practices, visualization solutions, and data analytics. He holds several patents ranging from biological agent decontamination solutions to a driving sensing/signaling device.
Before coming to Agilex, Dr. McKnight served as Senior Vice President and Director of Science and Technology Strategy at Science Applications International Corporation (SAIC). His responsibilities included technical collaboration corporate-wide, strategic technology investments (including IR&D), and validating innovation methodologies.
Dr. McKnight served on the Defense Science Board Summer Study on 21st Century Strategic Technology Vectors, National Science Foundation's Industry Expert Panel on Industrial R&D, Harvard Business Review Advisory Council, National Knowledge & Intellectual Property Management Task Force, and IBM's Global Innovation Outlook (GIO) Team. He has coauthored several technical books and recently published a book on youth soccer coaching – Soccer is a Thinking Game.
Dr. McKnight received a Bachelor's in Engineering Sciences from the United States Air Force Academy, a Master's in Mechanical Engineering from the University of New Mexico, and a Doctorate in Aerospace Engineering Sciences from the University of Colorado.
Joseph P. Miletich
Joseph Miletich is Senior Vice President of Research at Amgen and is a member of Amgen's senior management team. He directs the company's drug discovery efforts in basic research, as well as preclinical development and medical sciences worldwide.
Dr. Miletich joined Amgen from Merck Research Laboratories, where he was Senior Vice President of worldwide preclinical development. Before joining Merck, Dr. Miletich was Professor of Internal Medicine and Pathology at the Washington University School of Medicine in St Louis, and he held the additional position of Chief of the Division of Laboratory Medicine. He also served as Director of Laboratories at Barnes-Jewish Hospital in St Louis.
Dr. Miletich received his M.D. and Ph.D. in Molecular Biology from Washington University in St. Louis and trained in internal medicine at the University of California, San Francisco. He has authored numerous peer-reviewed manuscripts in the field of hematology and pathology and has served with distinction on expert scientific review groups and editorial boards.
Roger M. Perlmutter
Roger Perlmutter is Executive Vice President for Research and Development at Amgen. A graduate of Reed College (Portland, Oregon), Dr. Perlmutter received his M.D. and Ph.D. degrees from Washington University (St. Louis) in 1979. Thereafter he pursued clinical training in internal medicine at the Massachusetts General Hospital and at the University of California at San Francisco. From 1981 to 1984 he was a Lecturer in the Division of Biology at the California Institute of Technology. He joined the Departments of Medicine and Biochemistry and the Howard Hughes Medical Institute at the University of Washington (Seattle) in 1984, and in 1989 became Professor and founding Chairman of the Department of Immunology there. During this period, Dr. Perlmutter focused his scientific efforts on the elucidation of signaling pathways governing lymphocyte development and activation. In 1997 he left the University of Washington to join Merck and Co., ultimately rising to the rank of Executive Vice President, Worldwide Basic and Preclinical Research. He left Merck in 2001 to join Amgen in California.
Dr. Perlmutter is also a director of Stem Cells, Inc., a Trustee of Reed College, and Chairman of the Board of Directors of the Institute for Systems Biology, a not-for-profit research institute based in Seattle, Washington. He was previously President of the American Association of Immunologists, and is a Fellow of the American Academy of Arts and Sciences.
Philip C. Rueppel
Philip Rueppel joined Wachovia in June 2005 as a Managing Director in US Equity Research. He covers the Software Sector and provides Team Leadership for the Technology Research Franchise. He brings a range of expertise to this position: nearly 13 years of sell-side experience augmented with software industry experience and a stint in the private equity arena. Mr. Rueppel began his career in the software industry as Engineering and Marketing Manager at Hewlett-Packard.
Mr. Rueppel held senior research positions at Sanford Bernstein, Alex Brown, Deutsche Bank, and most recently was one of the initial founding partners at America's Growth Capital, where he was both a Research Analyst and Co-Director of Research. He had extensive experience staffing and building research teams, and complemented his sell-side expertise with buy-side and private equity experience as a Principal at TA Associates, where he evaluated both public and private investment opportunities. Mr. Rueppel has been a four-time Wall Street Journal All-Star Analyst.
Mr. Rueppel earned his B.S. in Electrical Engineering at Yale University and his M.B.A. at Harvard's Graduate School of Business.
Charles Slife is Vice President of Technology at the Clorox Company. He manages organizations responsible for identifying and acquiring new technologies, developing technologies to create new product opportunities, and providing technical support to the business units. He is co-leading Open Innovation activities which include a cross-functional business team to create major new business opportunities. He extensively leverages external resources throughout all phases of product creation and development. Prior to joining Clorox in 2006, Dr. Slife was Chief Technology Officer at The Gillette Company.
Dr. Slife received his B.S. in Chemistry from the University of Illinois, Urbana and his Ph.D. in Biochemistry from the University of Wisconsin, Madison. He carried out Postdoctoral work at The Johns Hopkins University and was an Associate Professor at Emory University prior to beginning his career at Gillette in 1989.
Darlene J. S. Solomon
Darlene Solomon is Agilent Chief Technology Officer and Vice President of Agilent Laboratories. Dr. Solomon's responsibilities include developing the company's long-term technology strategy and overseeing the alignment of Agilent's objectives with its centralized research and development activities.
Dr. Solomon brings extensive experience in R&D and management to her current leadership role at Agilent Labs. She joined Hewlett-Packard Laboratories in 1984 as a member of the technical staff, subsequently holding a variety of research and management positions there, including R&D manager for the Chemical and Biological Systems Department. She joined Agilent Technologies when the company was formed in 1999. Prior to being named to her current post, she held the dual role of director of the Life Sciences Technologies Laboratory within Agilent Labs, as well as senior director, research and development/technology, for Agilent's Life Sciences and Chemical Analysis business.
Dr. Solomon received a Bachelor's in Chemistry from Stanford University, a Doctorate in Inorganic Chemistry from the Massachusetts Institute of Technology, and completed Stanford University's Executive Development Program. With numerous patents and publications to her name, Dr. Solomon was inducted into the Women in Technology International's Hall of Fame in 2001, received the YWCA Tribute to Women and Industry Award in 2004, and was named to Diversity Journal's Women Worth Watching in 2007.
Dr. Solomon serves on a number of scientific boards. She chairs R&D for California's Blue Ribbon Task Force on Nanotechnology (Chair of R&D) and serves on external advisory boards for the National Science Foundation Nanobiotechnology Center, A-STAR Board for Singapore Economic Development, University of California at Davis, University of Southern California Viterbi School of Engineering, Joint Venture Technology Convergence Consortium, and Bay Area Science and Innovation Consortium (BASIC).
Michael D. Taylor
Michael Taylor is President & CEO of Ensemble Discovery Corporation, Cambridge, MA. Dr. Taylor joined Ensemble Discovery in July of 2007 with more than 20 years experience in the pharmaceutical industry.
Ensemble is a biotech company creating breakthrough classes of therapeutics and diagnostics based on its proprietary DNA-Programmed Chemistry(tm) (DPC(tm)) platform. Prior to joining Ensemble, Dr. Taylor was Senior Vice President for Pfizer's Global R&D division responsible for global project and portfolio management. In other positions with Pfizer (and previously Warner-Lambert/Parke-Davis), he led early and late-stage development projects across multiple therapeutic areas, including Lipitor(r) and Neurontin(r). His career includes extensive experience in drug discovery, licensing and business development, and managing R&D alliances with pharmaceutical and biotech partners. In addition to his R&D experience, he is active in investor development, government affairs, and public policy affecting the pharmaceutical industry. Until 2003 he was Adjunct Professor of Medicinal Chemistry at the College of Pharmacy at the University of Michigan, where he was active in teaching medicinal chemistry and biopharmaceutics.
Dr. Taylor has authored or coauthored 65 manuscripts and published abstracts and holds 6 patents. He holds a Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo and was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania.
Maria A. Thompson
Maria Thompson is President of Ann Arbor based T/J Technologies, the Advanced Research & Government Solutions Group of A123Systems, Inc. A123Systems is known internationally for its Nanophosphate™ lithium ion battery technology. Ms. Thompson was co founder, President, and CEO of T/J Technologies, Inc., a nationally recognized Michigan company for new materials development and cutting-edge research, which was acquired by A123Systems Inc. in 2006. Combined, the organizations represent the largest lithium-ion R&D team in North America, with world-class expertise and management, and global manufacturing operations. A123Systems is one of the world's leading suppliers of high-power lithium-ion batteries.
Under Ms. Thompson's leadership, T/J Technologies attracted national and regional recognition. NASA Headquarters honored T/J Technologies with a “Special Recognition Award” presented by NASA Administrator, Dr. Michael Griffin. It was also named one of “50 Companies to Watch in Michigan,” and Crain's Detroit Business chose the company as one of the “20 Largest Technology-Based Companies.” It also received the Nunn/Perry Award from the Department of Defense for its ultracapacitor development with Lockheed Martin.
Crain's Detroit Business chose Ms. Thompson as one of Detroit's Most Influential Women in 2007 and named her as one of Metro Detroit's Innovators in 2000. She was invited to speak to the U.S. House Committee on Small Business as part of the Small Business Administration's 50th Anniversary. Additional recognition includes awards from NASA Glenn Research Center, the Small Business Foundation of Michigan, and The Small Business Association of Michigan.
Ms. Thompson is a member of Ann Arbor SPARK's Board of Directors, the Zell Lurie Institute Advisory Board, and The Michigan Small Business Foundation. She also served for 6 years on the Advanced Technology Advisory Board for the National Institute of Standards and Technology (NIST), and is a former member of several non-profit organization boards. Ms. Thompson earned an M.B.A. from the University of Michigan Business School. Prior to starting T/J Technologies, Ms. Thompson worked at Steelcase and IBM, where she earned numerous company awards.
Robert Zivin is the Corporate Director in the Corporate Office of Science & Technology (COSAT), Johnson & Johnson. He joined Johnson & Johnson in 1986 as a Senior Scientist at Ortho Diagnostic Systems, Inc. (today's OCD). Dr. Zivin was a member of the team that brought the first DNA probe-based, colorimetric assay to FDC approval. He joined the Biotech Division of the R.W. Johnson Pharmaceutical Research Institute (today's J&J PRD) in 1989, where he led the Antibody Humanization Project. Several of the molecules (huOKT3, huOKT4A, hu-anti-Tissue Factor) produced in that effort are, or have been the subject of clinical or pre-clinical development. In 1995, Dr. Zivin established the Exploratory Technology team in RWJ PRI, and was responsible for the evaluation and development of new discovery technologies. He joined COSAT in 2003.
Prior to Johnson & Johnson, Dr. Zivin was a Senior Research Scientist at Merck, Sharpe & Dohme Research Laboratories. While there, he led the team that cloned the first cardiac atrial peptide (ANF).
Dr. Zivin received a B.S. in Biology from Northern Illinois University and a Ph.D. in Microbiology from the University of Chicago. He subsequently completed a Postdoctoral Fellowship at the National Cancer Institute.